Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2005  2006  2007  2008  2009
<<<        >

Booth-Genthe C.L., Louie S.S., Carlini E.J., Li B., Eisenhandler R., Hochman J.H., Mei Q., Kim R.B., Rushmore T.H., and Yamazaki M.: Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): Comparison of rat P-glycoprotein transport to human and mouse. J Pharmacol Toxicol Methods. 54:78-89, 2006. [Pubmed]

Chen X., Chen F., Liu S., Glaeser H., Dawson P.A., Hofmann A.F., Kim R.B., Shneider B.L., and Pang K.S.: Transactivation of rat Asbt and increased bile acid transport by 1,25-dihydroxyvitamin D3 via the vitamin D receptor (VDR). Mol. Pharmacol. 69:1913-1923, 2006. [Pubmed]

Choo E.F., Kurnik D., Muszkat M., Ohkubo T., Shay S.D., Higginbotham J.N., Glaeser H., Kim R.B., Wood A.J.J., and Wilkinson G.R.: Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes and the blood-brain barrier . J. Pharmacol. Exp. Ther. 317:1012-1018, 2006 [Pubmed]

Haas D.W., Bartlett J.A., Andersen J.W., Sanne I., Wilkinson G.R., Hinkle J., Rousseau F., Ingram C.D., Shaw A., Lederman M.M., and Kim R.B.: Pharmacogenetics of nevirapine-associated hepatotoxicity: An adult AIDS Clinical Trials Group Collaboration. Clin. Infect Dis, 43:783-786, 2006. [Pubmed]

Ho R.H., Tirona R.G., Leake B.F., Glaeser H., Lee W., Lemke C.J., Wang Y., and Kim R.B.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806, 2006.  [Pubmed]

Katz D.A., Carr R., Grimm D.R., Xiong H., Holley-Shanks R., Mueller T., Leake B., Wang W., Han L., Wang P.G., Chang P.G., Chang M.S., Ediki T., Sahelijo L., Doan T., Allen A., Spears B.B., and Kim R.B.: OATP1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin. Pharmacol. Ther., 79:186-196, 2006.  [Pubmed]

Kim R.B.: Transporters in drug discovery: why, when and how. Mol. Pharm. 3: 26-32, 2006 [Pubmed]

McRae M.P., Lowe C.M., Tian X., Bourdet D.L., Ho R.H., Leake B.F., Kim R.B., Brouwer K.L.R., Kashuba A.D.M.: Ritonavir, saquinavir and evfavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J. Pharmacol. Exp. Ther. 318:1068-1075, 2006. [Pubmed]

Motsinger A.A., Ritchie M.D., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D�Aquila R.T., Johnson V.A., Pollard R.B., Merigan T.C., Hirsch M.S., Donahue J.P., Kim R.B., and Haas D.W.: Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study. Pharmacogenet. Genomics. 16:837-845. [Pubmed]

Ribaudo H.J., Haas D.W., Tierney C., Kim R.B., Wilkinson G.R., Gulick R.M., Clifford D.B., Marzolini C., Fletcher C.B., Tashima K.T., Kuritzkes D.R., and Acosta E.P.: Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS Clinical Trials Group Study. Clin Infect. Dis. 42:401-407, 2006.  [Pubmed]

Ritchie M.D., Haas D.W., Motsinger A.A., Donahue J.P., Erdem H., Raffanti S., Rebeiro P., George A.L., Kim R.B., Haines J.L., Sternling T.R.: Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin. Infect Dis, 43:779-782, 2006. [Pubmed]

Sankaralingam S., Desai K.M., Glaeser H., Kim R.B., and Wilson T.W.: Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. Am. J. Hypertension. 19:1174-1180, 2006. [Pubmed]

Schwarz U.I., Johnston P.E., Bailey D.G., Kim R.B., Mayo G., and Milstone A.: Impact of citrus soft drinks relative to grapefruit juice on cyclosporine disposition. Br. J. Clin Pharmacol. 62:485-491, 2006 [Pubmed]